https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-18 / BMC Cancer 2018 Jul;18(1):746
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-18 / BMC Cancer 2018 Jul;18(1):7462018-07-18 00:00:002018-07-18 00:00:00Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-11 / Cancer Res. 2015 Apr;75(7):1265-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-11 / Cancer Res. 2015 Apr;75(7):1265-742015-02-11 00:00:002019-02-15 08:53:32Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor β
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-11-01 / J. Exp. Clin. Cancer Res. 2014 Nov;33:91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-11-01 / J. Exp. Clin. Cancer Res. 2014 Nov;33:912014-11-01 00:00:002014-11-01 00:00:00Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-10 / Korean J. Physiol. Pharmacol. 2012 Aug;16(4):243-72012-08-10 00:00:002019-02-15 08:53:36Morphologic evidence of anti-tumor specificity of T cells activated by denritic cells derived from peripheral blood mononuclear cells of thyroid cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-29 / J Oncol 2010;2010:179491
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-29 / J Oncol 2010;2010:1794912010-06-29 00:00:002019-02-15 08:53:21Advances in cellular therapy for the treatment of thyroid cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-07-01 / J. Intern. Med. 2009 Jul;266(1):99-113
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-07-01 / J. Intern. Med. 2009 Jul;266(1):99-1132009-07-01 00:00:002019-02-15 08:53:36Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Oncol. Rep. 2009 Jun;21(6):1585-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Oncol. Rep. 2009 Jun;21(6):1585-922009-06-01 00:00:002019-02-15 08:53:21Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-3052008-07-01 00:00:002019-02-15 08:53:22Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-02-01 / Horm. Metab. Res. 2008 Feb;40(2):108-162008-02-01 00:00:002019-02-15 08:53:23Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / Thyroid 2007 Jan;17(1):53-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / Thyroid 2007 Jan;17(1):53-82007-01-01 00:00:002019-02-15 08:53:25Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer
